Cargando…

Influence of Naproxen, Age and Body Mass Index on the Biological Composition of Leukocyte Rich Platelet-Rich Plasma: A Prospective, Therapeutic, Cohort Study

OBJECTIVES: Platelet-rich plasma (PRP) is comprised of several biologically active factors that can stimulate musculoskeletal healing processes. Non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat many musculoskeletal conditions and influence platelet function. The influence of NSAIDs o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mannava, Sandeep, Whitney, Kaitlyn E., King, Jillian, Kennedy, Mitchell, Klett, Katarina, Dornan, Grant, Chahla, Jorge, Evans, Thos A., Huard, Johnny, LaPrade, Robert F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094783/
http://dx.doi.org/10.1177/2325967118S00113
_version_ 1783347863477026816
author Mannava, Sandeep
Whitney, Kaitlyn E.
King, Jillian
Kennedy, Mitchell
Klett, Katarina
Dornan, Grant
Chahla, Jorge
Evans, Thos A.
Huard, Johnny
LaPrade, Robert F.
author_facet Mannava, Sandeep
Whitney, Kaitlyn E.
King, Jillian
Kennedy, Mitchell
Klett, Katarina
Dornan, Grant
Chahla, Jorge
Evans, Thos A.
Huard, Johnny
LaPrade, Robert F.
author_sort Mannava, Sandeep
collection PubMed
description OBJECTIVES: Platelet-rich plasma (PRP) is comprised of several biologically active factors that can stimulate musculoskeletal healing processes. Non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat many musculoskeletal conditions and influence platelet function. The influence of NSAIDs on the biological composition of PRP is not well known. The purpose of this study was to quantify and compare growth factors and other chemokines and cytokines in leukocyte-rich PRP (LR-PRP) between baseline, following one-week of NSAID (Naproxen) use, and after a one-week washout period. We hypothesized that Naproxen would alter both the catabolic and anabolic factors in LR-PRP. Our secondary hypothesis was that discontinuing Naproxen use for one-week would be sufficient to return LR-PRP’s molecular constituents back to baseline. STUDY DESIGN: Non-randomized, prospective cohort study; Level of evidence: 2. METHODS: Sixteen healthy volunteers (n=8 male and n=8 females) were enrolled in this IRB approved study. Peripheral blood was drawn at three-time points: baseline, one-week after Naproxen intake, and after a one-week washout period. Donors were instructed after the first blood-draw to ingest oral Naproxen tablets twice a day (440 mg bid) for one-week. Fifty-two anabolic and catabolic factors in LR-PRP were measured at all time points. Donor demographics were collected at the time of the initial blood-draw. To address the primary hypothesis of this study, Friedman’s test was used to identify significant differences between the baseline, Naproxen and washout time points while accounting for the repeated measures design of this study. When Friedman’s test was significant, pairwise comparisons were made using Holm’s method to control the family-wise type 1 error rate. RESULTS: Three anabolic growth factors, platelet derived growth factor-AA (PDGF-AA, Figure 1), platelet derived growth factor-AB (PDGF-AB, Figure 1), and transforming growth factor-β1 (TGF-β1), had a significant decline from baseline (p<0.05) after one-week of Naproxen use. There was a significant recovery (p<0.05) of PDGF-AA and PDGF-AB levels after the one-week washout of NSAIDs, with a return to baseline levels. TGF-β1 did not recover to baseline levels after a one-week washout period. Catabolic factors tumor necrosis factor-β (TNF-β) and interleukin-6 (IL-6) had a significant decline from baseline (p<0.05) after NSAID use for one-week and returned to levels similar to baseline (p<0.05) after a one-week washout period. CONCLUSION: Naproxen use diminished several biological factors in LR-PRP; however, a one-week washout period was sufficient for the recovery of PDGF-AA, PDGF-AB, TNF-β, and IL-6 to return to baseline levels. Our results suggest that patients undergoing PRP treatment should discontinue Naproxen, and other NSAID use, at least one-week prior to harvest and injection of PRP.
format Online
Article
Text
id pubmed-6094783
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-60947832018-08-23 Influence of Naproxen, Age and Body Mass Index on the Biological Composition of Leukocyte Rich Platelet-Rich Plasma: A Prospective, Therapeutic, Cohort Study Mannava, Sandeep Whitney, Kaitlyn E. King, Jillian Kennedy, Mitchell Klett, Katarina Dornan, Grant Chahla, Jorge Evans, Thos A. Huard, Johnny LaPrade, Robert F. Orthop J Sports Med Article OBJECTIVES: Platelet-rich plasma (PRP) is comprised of several biologically active factors that can stimulate musculoskeletal healing processes. Non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat many musculoskeletal conditions and influence platelet function. The influence of NSAIDs on the biological composition of PRP is not well known. The purpose of this study was to quantify and compare growth factors and other chemokines and cytokines in leukocyte-rich PRP (LR-PRP) between baseline, following one-week of NSAID (Naproxen) use, and after a one-week washout period. We hypothesized that Naproxen would alter both the catabolic and anabolic factors in LR-PRP. Our secondary hypothesis was that discontinuing Naproxen use for one-week would be sufficient to return LR-PRP’s molecular constituents back to baseline. STUDY DESIGN: Non-randomized, prospective cohort study; Level of evidence: 2. METHODS: Sixteen healthy volunteers (n=8 male and n=8 females) were enrolled in this IRB approved study. Peripheral blood was drawn at three-time points: baseline, one-week after Naproxen intake, and after a one-week washout period. Donors were instructed after the first blood-draw to ingest oral Naproxen tablets twice a day (440 mg bid) for one-week. Fifty-two anabolic and catabolic factors in LR-PRP were measured at all time points. Donor demographics were collected at the time of the initial blood-draw. To address the primary hypothesis of this study, Friedman’s test was used to identify significant differences between the baseline, Naproxen and washout time points while accounting for the repeated measures design of this study. When Friedman’s test was significant, pairwise comparisons were made using Holm’s method to control the family-wise type 1 error rate. RESULTS: Three anabolic growth factors, platelet derived growth factor-AA (PDGF-AA, Figure 1), platelet derived growth factor-AB (PDGF-AB, Figure 1), and transforming growth factor-β1 (TGF-β1), had a significant decline from baseline (p<0.05) after one-week of Naproxen use. There was a significant recovery (p<0.05) of PDGF-AA and PDGF-AB levels after the one-week washout of NSAIDs, with a return to baseline levels. TGF-β1 did not recover to baseline levels after a one-week washout period. Catabolic factors tumor necrosis factor-β (TNF-β) and interleukin-6 (IL-6) had a significant decline from baseline (p<0.05) after NSAID use for one-week and returned to levels similar to baseline (p<0.05) after a one-week washout period. CONCLUSION: Naproxen use diminished several biological factors in LR-PRP; however, a one-week washout period was sufficient for the recovery of PDGF-AA, PDGF-AB, TNF-β, and IL-6 to return to baseline levels. Our results suggest that patients undergoing PRP treatment should discontinue Naproxen, and other NSAID use, at least one-week prior to harvest and injection of PRP. SAGE Publications 2018-07-27 /pmc/articles/PMC6094783/ http://dx.doi.org/10.1177/2325967118S00113 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc-nd/4.0/ This open-access article is published and distributed under the Creative Commons Attribution - NonCommercial - No Derivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits the noncommercial use, distribution, and reproduction of the article in any medium, provided the original author and source are credited. You may not alter, transform, or build upon this article without the permission of the Author(s). For article reuse guidelines, please visit SAGE’s website at http://www.sagepub.com/journals-permissions.
spellingShingle Article
Mannava, Sandeep
Whitney, Kaitlyn E.
King, Jillian
Kennedy, Mitchell
Klett, Katarina
Dornan, Grant
Chahla, Jorge
Evans, Thos A.
Huard, Johnny
LaPrade, Robert F.
Influence of Naproxen, Age and Body Mass Index on the Biological Composition of Leukocyte Rich Platelet-Rich Plasma: A Prospective, Therapeutic, Cohort Study
title Influence of Naproxen, Age and Body Mass Index on the Biological Composition of Leukocyte Rich Platelet-Rich Plasma: A Prospective, Therapeutic, Cohort Study
title_full Influence of Naproxen, Age and Body Mass Index on the Biological Composition of Leukocyte Rich Platelet-Rich Plasma: A Prospective, Therapeutic, Cohort Study
title_fullStr Influence of Naproxen, Age and Body Mass Index on the Biological Composition of Leukocyte Rich Platelet-Rich Plasma: A Prospective, Therapeutic, Cohort Study
title_full_unstemmed Influence of Naproxen, Age and Body Mass Index on the Biological Composition of Leukocyte Rich Platelet-Rich Plasma: A Prospective, Therapeutic, Cohort Study
title_short Influence of Naproxen, Age and Body Mass Index on the Biological Composition of Leukocyte Rich Platelet-Rich Plasma: A Prospective, Therapeutic, Cohort Study
title_sort influence of naproxen, age and body mass index on the biological composition of leukocyte rich platelet-rich plasma: a prospective, therapeutic, cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094783/
http://dx.doi.org/10.1177/2325967118S00113
work_keys_str_mv AT mannavasandeep influenceofnaproxenageandbodymassindexonthebiologicalcompositionofleukocyterichplateletrichplasmaaprospectivetherapeuticcohortstudy
AT whitneykaitlyne influenceofnaproxenageandbodymassindexonthebiologicalcompositionofleukocyterichplateletrichplasmaaprospectivetherapeuticcohortstudy
AT kingjillian influenceofnaproxenageandbodymassindexonthebiologicalcompositionofleukocyterichplateletrichplasmaaprospectivetherapeuticcohortstudy
AT kennedymitchell influenceofnaproxenageandbodymassindexonthebiologicalcompositionofleukocyterichplateletrichplasmaaprospectivetherapeuticcohortstudy
AT klettkatarina influenceofnaproxenageandbodymassindexonthebiologicalcompositionofleukocyterichplateletrichplasmaaprospectivetherapeuticcohortstudy
AT dornangrant influenceofnaproxenageandbodymassindexonthebiologicalcompositionofleukocyterichplateletrichplasmaaprospectivetherapeuticcohortstudy
AT chahlajorge influenceofnaproxenageandbodymassindexonthebiologicalcompositionofleukocyterichplateletrichplasmaaprospectivetherapeuticcohortstudy
AT evansthosa influenceofnaproxenageandbodymassindexonthebiologicalcompositionofleukocyterichplateletrichplasmaaprospectivetherapeuticcohortstudy
AT huardjohnny influenceofnaproxenageandbodymassindexonthebiologicalcompositionofleukocyterichplateletrichplasmaaprospectivetherapeuticcohortstudy
AT lapraderobertf influenceofnaproxenageandbodymassindexonthebiologicalcompositionofleukocyterichplateletrichplasmaaprospectivetherapeuticcohortstudy